NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.
Able to provide informed consent
Huntingtin gene expansion carrier with >= 39 CAG repeats
Absence of unequivocal motor signs of HD - that is, UHDRS
Diagnostic Confidence Level needs to be <4 upon enrolment
Diagnosis of clinical HD
Known hypersensitivity to NAC
Pregnancy, breastfeeding or intention to do so prior to the end of the study
Exposure to any investigational drugs within 30 days of Baseline Visit
Western Sydney Local Health District
Lead sponsor
Deakin University
Collaborator
Monash University
Collaborator
Royal Perth Hospital
Collaborator
The University of Queensland
Collaborator
University of Melbourne
Collaborator